Nabors Industries Ltd Stock News

Nabors (NBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Nabors (NBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Nabors (NBR) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made

Nabors (NBR) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made

Within the last quarter, Nabors Industries (NYSE:NBR) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 1 3 0 Last

Nabors (NBR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. Grindr Inc. (NYSE: GRND) shares dippe

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. NeuroOne Medical Techn

Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares jumped 104% to $35.50 after Merck announced it would acquire the company for $36 per share in cash. Nexalin Technology, Inc. (NASDAQ: NXL) jumpe

Analysts have provided the following ratings for Nabors Industries (NYSE:NBR) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 1 3 0

Nabors' (NBR) third-quarter 2022 loss from operations is broader than the Zacks Consensus Estimate, while quarterly revenues beat the consensus mark.

Nabors' (NBR) third-quarter 2022 loss from operations is broader than the Zacks Consensus Estimate, while quarterly revenues beat the consensus mark.

Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At th

Nabors Industries Ltd. (NYSE:NBR ) Q3 2022 Earnings Conference Call October 26, 2022 2:00 PM ET Company Participants William Conroy – Vice President of Investor Relations and Corporate Development T

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping more than 200 points on Wednesday. The Dow traded down 0.03% to 31,825.65 while the NASDAQ fell 1.91% to